Galmed PharmaceuticalsEOCN
13F holders, Q2 2026 (June 30)14holders −2
2new positions
4sold out
1famous investor
$0.55avg. 13F price*
At the end of Q2 2026, 14 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings, down 2 from Q1 2026. 2 opened new positions and 4 sold out. The largest holders were Citadel Advisors ($48K), HRT Financial LP ($23K) and XTX Topco Ltd ($8K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $23K |
| Exits | 4 | $48K |
All 13F filers, Q1 2026 → Q2 2026: 118,159 shares bought and 108,207 shares sold, net +9,952 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Citadel Advisors | 0.00% | Add +663.1% | 86,851 | $48K |
| HRT Financial LP | 0.00% | New | 42,090 | $23K |
| XTX Topco Ltd | 0.00% | Reduce -33.0% | 15,015 | $8K |
| Two Sigma Securities, LLC | 0.00% | Reduce -8.0% | 11,012 | $6K |
| SBI Securities Co., Ltd. | 0.00% | Add +312.5% | 66 | $37 |
| Morgan Stanley | 0.00% | Reduce -64.3% | 56 | $31 |
| Wells Fargo & Company | 0.00% | No change | 43 | $24 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 14 | $8 |
| Allworth Financial LP | 0.00% | No change | 2 | $2 |
| UBS Group AG | 0.00% | Reduce -99.9% | 3 | $2 |
| Osaic Holdings, Inc. | 0.00% | No change | 5 | $2 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 1 | $1 |
| Royal Bank of Canada | 0.00% | New | 550 | $0 |
| Tsfg, LLC | 0.00% | No change | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.